<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291785</url>
  </required_header>
  <id_info>
    <org_study_id>CAM201</org_study_id>
    <nct_id>NCT00291785</nct_id>
  </id_info>
  <brief_title>Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer</brief_title>
  <official_title>Phase I/II Study of CT-2106 in Combination With Infusional 5-fluorouracil/Folinic Acid (5-FU/FA)(de Gramont Schedule) as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FU/FA Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CT-2106, a camptothecin (CPT) conjugate, is a new generation of topoisomerase I inhibitors
      designed to deliver higher, more effective chemotherapy to tumor tissue with less toxicity to
      normal tissues. The objective of this study is to determine the dose limiting toxicities,
      safety profile and antitumor activity of CT-2016 in combination with 5-FU and folic acid for
      the treatment of colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: determine the Maximum Tolerated Dose, dose limiting toxicities, safety profile and antitumor activity</measure>
    <time_frame>Each cycle</time_frame>
  </primary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-2106</intervention_name>
    <description>CT-2106 as 10 minute infusion on days 1, 15 &amp; 29 of each 42-day cycle</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
    <description>Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU (fluorouracil)</intervention_name>
    <description>5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven metastatic colorectal adenocarcinoma, failing one prior
             treatment containing oxaliplatin plus 5-FU/FA

          -  At least one measurable lesion according to RECIST criteria for both Phase I and II

          -  ECOG performance status 0 or 1

          -  Adequate hematologic, renal and hepatic function

          -  Wash out period of at least 4 weeks from surgery, 4 weeks from radiotherapy

        Exclusion Criteria:

          -  Past or concurrent history of neoplasm other than colorectal adenocarcinoma, except
             curatively treated non melanoma skin cancer or in situ carcinoma of the cervix.

          -  Pregnant or lactating patients

          -  Prior treatment with camptothecins

          -  Presence or history of CNS metastasis or carcinomatous leptomeningitis

          -  Current active infection per investigator assessment

          -  Unresolved bowel obstruction or partial obstruction, uncontrolled Crohn's disease or
             ulcerative colitis

          -  Current history of chronic diarrhea greater than or equal to grade 1 (CTCAE version 3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barone C., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Universitario &quot;A.Gemelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Universitario &quot;A.Gemelli&quot;</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Igor Gorbatchevsky,M.D.</name_title>
    <organization>Cell Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>camptothecin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

